The Relationship Between the Differential Expression of FosB Protein in Laryngeal Cancer Tissues and Clinical Prognosis

February 14, 2025 updated by: Yang ji

Expression of FosB Gene in Laryngeal Cancer Tissues and It's Clinical Prognosis Significance

To determine whether there is statisstical difference in FosB (FBJ murine osteosarcoma viral oncogene homolog B) protein expression between laryngeal cancer tissue and adjacent tissue through immunohistochemistry methods.

If there are differences, further the investigators will collect relevant patients information,such as clinical stages, pathological types, clinical prognosis and so on. ultimately analyze whether it is related to the expression of FOsB in laryngeal cancer tissue and adjacent tissues

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

First,the investigators will collect 100 to 200 cases of laryngeal cancer patients who have been finally diagnosed and treated in our institution in the past five years. Laryngeal cancer pathological tissues and adjacent tissues will be selected to make pathological sections. Use immunohistochemistry to confirm the differences in FosB protein between laryngeal cancer tissues and adjacent tissues, and clarify whether there are differences.

secondly,if there are differences, further the investigators will collect relevant patients information,such as clinical stages, pathological types, clinical prognosis and so on. Review the clinical data of corresponding patients, including age, gender, smoking and alcohol history, clinical stages, pathological types and clinical prognosis, etc., and compare whether there are statistical differences.

Finally, clinical prognostic data of relevant patients were collected through outpatient follow-up, online and telephone follow-up, to determine whether there is a correlation between Fosb expression in laryngeal cancer tissue and clinical prognosis.

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • China/SiChuan
      • Nanchong, China/SiChuan, China, 637000
        • Cllinical Laboratory of Chuanbei Medical College
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Researchers are Collecting 100 to 200 cases of laryngeal cancer patients who have been finally diagnosed and treated in research institution.

Description

Inclusion Criteria:

  • laryngeal squamous cell carcinoma was diagnosed ,and biopsy was confirmed by two pathologists;
  • Primary tumor of Laryngeal ,and there was no distant metastasis;
  • Standard treatment such as surgery and Preliminarily-diagnosed parients;
  • full clinical and pathological data information and good follow-up;
  • there was no previous fatal diseases such as complicated tumors.

Exclusion Criteria:

  • Secondary cancer or cancer with distant metastasis;
  • Patients who have not seen a doctor for the first time or have received surgery or radiotherapy or chemotherapy in other hospitals;
  • Clinical and pathological data were missing and loss to follow-up;
  • Patients who abandoned treatment or standard treatment procedures has not been completed;
  • The past medical history of other lethal diseases such as complicated tumors.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
The expression of FosB positive group
Researcher will incorporate the positive expression of FosB protein in laryngeal cancer tissues into the positive study group by immunohistochemical methods!
Other: the expression positive in laryngeal cancer tissue
Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!
The expression of FosB negative group
Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!
Other: the expression negative in laryngeal cancer tissue
Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the number of fosb gene positive expression cases in laryngeal carcinoma cells and adjacent tissues was determined.
Time Frame: one month
the number of fosb gene positive expression cases in laryngeal carcinoma cells and adjacent tissues was determined by immunohistochemical test of pathological sections.
one month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
_Experimental result of western blot and PCR._Correlation analysis data between clinical information and experimental results..
Time Frame: three months
Researcher will verify the effection of FosB gene on the proliferation and migration of Hep-2 laryngeal cancer cells through a series of basic experiments,such as Immunohistochemistry,western blot,PCR,and so on.clinical prognoostic information of patients was collected and the relationship with fosb gene expression was analyzed.
three months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Yang ji

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2025

Primary Completion (Estimated)

April 1, 2025

Study Completion (Estimated)

May 1, 2025

Study Registration Dates

First Submitted

August 17, 2024

First Submitted That Met QC Criteria

February 14, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 14, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NeijiangPH2

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Laryngeal Carcinoma

Clinical Trials on the expression positive in laryngeal cancer tissue

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe